US 12,421,304 B2
Method for inhibiting bone resorption
Ian Desmond Padhi, Newbury Park, CA (US); and Graham Richard Jang, Santa Monica, CA (US)
Assigned to AMGEN INC., Thousand Oaks, CA (US)
Filed by AMGEN INC., Thousand Oaks, CA (US)
Filed on Jul. 15, 2021, as Appl. No. 17/376,304.
Application 13/090,075 is a division of application No. 12/212,327, filed on Sep. 17, 2008, granted, now 8,017,120.
Application 17/376,304 is a continuation of application No. 16/191,068, filed on Nov. 14, 2018, granted, now 11,091,537.
Application 16/191,068 is a continuation of application No. 14/740,838, filed on Jun. 16, 2015, granted, now 10,273,293.
Application 14/740,838 is a continuation of application No. 13/860,954, filed on Apr. 11, 2013, granted, now 9,089,553.
Application 13/860,954 is a continuation of application No. 13/090,075, filed on Apr. 19, 2011, granted, now 8,440,193.
Claims priority of provisional application 60/973,024, filed on Sep. 17, 2007.
Prior Publication US 2021/0340236 A1, Nov. 4, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/40 (2006.01); A61K 39/395 (2006.01); C07K 16/18 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/18 (2013.01) [A61K 39/3955 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01)] 7 Claims
 
1. A method for treating osteogenesis imperfecta in a subject in need thereof, the method comprising administering to the subject an anti-sclerostin antibody that cross-blocks the binding of an antibody comprising heavy chains of SEQ ID NO: 209 and light chains of SEQ ID NO: 205 to sclerostin in an amount from about 1 mg/kg to about 3 mg/kg.